Figure 5 | Cell Death & Disease

Figure 5

From: MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway

Figure 5

HBx inhibits p53-mediated activation of miR-216b and upregulates IGF2BP2. (a) RT-PCR assay for miR-216b and western blotting analysis for IGF2BP2 in vector-, HBs-, HBc-, HBp- or HBx-expressing cells. (b) RT-PCR analysis for miR-216b and pre-miR-216b and western blotting analysis for IGF2BP2 in two HCC cell lines, HepG2 and SMMC-7721, transfected with HBx at different doses and controls. (c) RT-PCR analysis for miR-216b and pre-miR-216b and western blotting analysis for IGF2BP2 in HepG2 and HepG2.2.15 cells with or without HBx inhibition. (d) Dual-luciferase assay of the putative miR-216b promoter in HepG2 and SMMC-7721 cells transfected with HBx and controls. (d) HepG2 cells were transfected with p53 or p53 mutant (R249S) and analyzed for miR-216b expression by real-time RT-PCR and for IGF2BP2 expression by western blotting. (e and f) HepG2 cells were transfected with HBx and p53 siRNAs or control siRNA and analyzed as in a. (g) ChIP analysis showed that HBx inhibited p53 occupying on the putative miR-216b promoter in HepG2 cells. The data represent the mean±S.D. (*P<0.05)

Back to article page